Phaseline

Companies › Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.: clinical trials, targets and expected readouts

8 active drug programs in 25 registered trials: 11 Phase 3, 8 Phase 1, 4 Phase 2, 2 Phase 4; Metabolic and endocrine, Cardiovascular, Genitourinary, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GZR4
GLP-1 receptor agonist
GLP1RPhase 3DiabetesNov 2026
GZR18 injection
GLP-1 receptor agonist
–Phase 3Obesity/Overweight; Type 2 Diabetes Mellitus (T2DM); Obesity/Overweight in Adult; Overweight or Obesity …Dec 2026
GZR33 Injection–Phase 3Type 2 Diabetes (T2DM)Apr 2027
Bempedoic Acid
ATP-citrate synthase inhibitor
ACLYPhase 3Primary Hyperlipidemia; Acute Coronary Syndromes; Rheumatoid Arthritis (RA); Dyslipidemias …–
GZR102–Phase 2Type 2 Diabetes Mellitus (T2DM)Jan 2027
GZC8072 Tablets–Phase 1Healthy Subjects;Overweight or ObesityAug 2027
GZR33
Long-acting basal insulin analogue
INSPhase 1Type 1 Diabetes Mellitis–
Insulin Degludec
Insulin receptor agonist
INSRPhase 1Type 2 Diabetes–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07141030GZR18 injectionPhase 1Obesity/OverweightMetabolic and endocrineOct 2025
NCT06780410Bempedoic AcidPhase 3Primary HyperlipidemiaMetabolic and endocrineOct 2025
NCT06767748GZR4Phase 3DiabetesMetabolic and endocrineFeb 2026
NCT07242664GZR33Phase 1Type 1 Diabetes MellitisMetabolic and endocrineFeb 2026
NCT06767761GZR4Phase 3DiabetesMetabolic and endocrineMar 2026
NCT07146347Insulin DegludecPhase 1Type 2 DiabetesMetabolic and endocrineApr 2026
NCT06728124GZR18 injectionPhase 3Obesity/OverweightMetabolic and endocrineMay 2026
NCT07355738GZR18 injectionPhase 1Obesity&T2DMetabolic and endocrineMay 2026
NCT07128888GZR18 injectionPhase 1Obesity or OverweightMetabolic and endocrineJul 2026
NCT07193147GZR4Phase 1DiabetesMetabolic and endocrineJul 2026
NCT06767735GZR4Phase 3DiabetesMetabolic and endocrineAug 2026
NCT07165223GZR4Phase 3DiabetesMetabolic and endocrineNov 2026
NCT06778967GZR18 injectionPhase 3Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineDec 2026
NCT07055386GZR18 injectionPhase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineJan 2027
NCT07055386GZR102Phase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineJan 2027
NCT07144098GZR18 injectionPhase 1Obesity/OverweightMetabolic and endocrineJan 2027
NCT06777238GZR18 injectionPhase 3Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineMar 2027
NCT07527078GZR33 InjectionPhase 3Type 2 Diabetes (T2DM)Metabolic and endocrineApr 2027
NCT07150975GZR18 injectionPhase 3Obesity/Overweight in AdultMetabolic and endocrineJun 2027
NCT07784699GZC8072 TabletsPhase 1Healthy Subjects;Overweight or ObesityMetabolic and endocrineAug 2027
NCT07292441GZR18 injectionPhase 3Overweight or ObesityMetabolic and endocrineSep 2027
NCT05488431Bempedoic AcidPhase 2DyslipidemiasCardiovascularMar 2028
NCT07824323Bempedoic AcidPhase 4Acute Coronary SyndromesCardiovascularMar 2028
NCT07282821Bempedoic AcidPhase 2ADPKD (Autosomal Dominant Polycystic Kidney Disease)GenitourinarySep 2029
NCT07611747Bempedoic AcidPhase 4Rheumatoid Arthritis (RA)ImmunologyApr 2031

From the company's SEC filings

Complete response letters from FDA

Targets

GLP1R (1) INS (1) ACLY (1) INSR (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Beijing QL Biopharmaceutical Viking Therapeutics Ascletis Pharma (China) The United Bio-Technology (Hengqin) Chendu DIAO Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.